TET2 mutations in the different PTCL entities
| PTCL entity . | TET2 mutation . | ||
|---|---|---|---|
| n . | n . | % . | |
| AITL | 86 | 40 | 47 |
| PTCL NOS* | 58 | 22 | 38 |
| TFH-like | 24 | 14 | 58 |
| Others | 34 | 8 | 24 |
| ALCL | 18 | 0 | 0 |
| EATL* | 10 | 2 | 20 |
| Extranodal NK/T | 12 | 0 | 0 |
| HSTL | 6 | 0 | 0 |
| Total | 190 | 64 | 34 |
| PTCL entity . | TET2 mutation . | ||
|---|---|---|---|
| n . | n . | % . | |
| AITL | 86 | 40 | 47 |
| PTCL NOS* | 58 | 22 | 38 |
| TFH-like | 24 | 14 | 58 |
| Others | 34 | 8 | 24 |
| ALCL | 18 | 0 | 0 |
| EATL* | 10 | 2 | 20 |
| Extranodal NK/T | 12 | 0 | 0 |
| HSTL | 6 | 0 | 0 |
| Total | 190 | 64 | 34 |
ALCL indicates anaplastic large-cell lymphoma; HSTL, hepatosplenic T-cell lymphoma; EATL, enteropathy-associated T-cell lymphoma; and extranodal NK/T, extranodal NK/T-cell lymphoma, nasal-type.
TET2 mutations were found in 3 extranodal tissue samples (1 skin, 1 spleen, and 1 liver) diagnosed as PTCL-NOS and in 2 intestinal tissue samples diagnosed as EATL.